S&P 500   3,449.92 (+0.67%)
DOW   28,401.29 (+0.73%)
QQQ   284.55 (+0.26%)
AAPL   116.70 (+0.62%)
MSFT   214.80 (+0.27%)
FB   265.55 (+1.59%)
GOOGL   1,540.03 (+0.66%)
AMZN   3,214.93 (+0.24%)
TSLA   422.71 (-1.88%)
NVDA   543.63 (+0.69%)
BABA   308.79 (+1.15%)
CGC   18.85 (-4.85%)
GE   7.35 (+0.82%)
MU   53.44 (+1.54%)
AMD   81.47 (-0.65%)
T   26.83 (-0.19%)
F   7.77 (+2.37%)
ACB   4.26 (-9.55%)
GILD   60.17 (-0.66%)
NFLX   523.91 (-1.28%)
BA   167.53 (+0.25%)
BAC   24.08 (+1.52%)
DIS   124.32 (+0.07%)
S&P 500   3,449.92 (+0.67%)
DOW   28,401.29 (+0.73%)
QQQ   284.55 (+0.26%)
AAPL   116.70 (+0.62%)
MSFT   214.80 (+0.27%)
FB   265.55 (+1.59%)
GOOGL   1,540.03 (+0.66%)
AMZN   3,214.93 (+0.24%)
TSLA   422.71 (-1.88%)
NVDA   543.63 (+0.69%)
BABA   308.79 (+1.15%)
CGC   18.85 (-4.85%)
GE   7.35 (+0.82%)
MU   53.44 (+1.54%)
AMD   81.47 (-0.65%)
T   26.83 (-0.19%)
F   7.77 (+2.37%)
ACB   4.26 (-9.55%)
GILD   60.17 (-0.66%)
NFLX   523.91 (-1.28%)
BA   167.53 (+0.25%)
BAC   24.08 (+1.52%)
DIS   124.32 (+0.07%)
S&P 500   3,449.92 (+0.67%)
DOW   28,401.29 (+0.73%)
QQQ   284.55 (+0.26%)
AAPL   116.70 (+0.62%)
MSFT   214.80 (+0.27%)
FB   265.55 (+1.59%)
GOOGL   1,540.03 (+0.66%)
AMZN   3,214.93 (+0.24%)
TSLA   422.71 (-1.88%)
NVDA   543.63 (+0.69%)
BABA   308.79 (+1.15%)
CGC   18.85 (-4.85%)
GE   7.35 (+0.82%)
MU   53.44 (+1.54%)
AMD   81.47 (-0.65%)
T   26.83 (-0.19%)
F   7.77 (+2.37%)
ACB   4.26 (-9.55%)
GILD   60.17 (-0.66%)
NFLX   523.91 (-1.28%)
BA   167.53 (+0.25%)
BAC   24.08 (+1.52%)
DIS   124.32 (+0.07%)
S&P 500   3,449.92 (+0.67%)
DOW   28,401.29 (+0.73%)
QQQ   284.55 (+0.26%)
AAPL   116.70 (+0.62%)
MSFT   214.80 (+0.27%)
FB   265.55 (+1.59%)
GOOGL   1,540.03 (+0.66%)
AMZN   3,214.93 (+0.24%)
TSLA   422.71 (-1.88%)
NVDA   543.63 (+0.69%)
BABA   308.79 (+1.15%)
CGC   18.85 (-4.85%)
GE   7.35 (+0.82%)
MU   53.44 (+1.54%)
AMD   81.47 (-0.65%)
T   26.83 (-0.19%)
F   7.77 (+2.37%)
ACB   4.26 (-9.55%)
GILD   60.17 (-0.66%)
NFLX   523.91 (-1.28%)
BA   167.53 (+0.25%)
BAC   24.08 (+1.52%)
DIS   124.32 (+0.07%)
Log in
NASDAQ:ORGO

Organogenesis Stock Forecast, Price & News

$4.13
+0.01 (+0.24 %)
(As of 10/20/2020 10:37 AM ET)
Add
Compare
Today's Range
$4.05
Now: $4.13▼
$4.30
50-Day Range
$3.47
MA: $4.02▼
$4.76
52-Week Range
$2.47
Now: $4.13▼
$8.34
Volume4,846 shs
Average Volume143,335 shs
Market Capitalization$435.37 million
P/E RatioN/A
Dividend YieldN/A
Beta1.3
Organogenesis Holdings Inc., a regenerative medicine company, focuses on the development, manufacture, and commercialization of solutions for the advanced wound care, and surgical and sports medicine markets primarily in the United States. The company's advanced wound care products include Apligraf for the treatment of venous leg ulcers and diabetic foot ulcers (DFUs); Dermagraft for treating DFUs; PuraPly AM to address biofilm across a range of wound types; and Affinity and NuShield to address various wound sizes and types. Its surgical and sports medicine products comprise ReNu for in-office joint and tendon applications; NuCel for bony fusion in the spine and extremities; NuShield and Affinity for surgical applications in targeted soft tissue repairs; and PuraPly AM for the surgical treatment of open wounds. The company's pipeline products include TransCyte for the treatment of second- and third-degree burns; PuraForce, a bioengineered porcine collagen surgical matrix for use in soft tissue reinforcement applications; Novachor for the treatment of chronic and acute wounds; Gintuit for the treatment of mucogingival conditions in adults; and PuraPly XT and PuraPly MZ for the treatment of chronic and acute wounds, as well as for surgical treatment of open wounds. It serves hospitals, wound care centers, government facilities, ambulatory service centers, and physician offices. The company sells its products through direct sales representatives and independent agencies. Organogenesis Holdings Inc. was founded in 1985 and is headquartered in Canton, Massachusetts.
Read More

Beat the Market (BTM) Rank™

Analyst Opinion: 3.5Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank™

1.53 out of 5 stars

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ORGO
Previous Symbol
CUSIPN/A
CIKN/A
Weborganogenesis.com
Phone781-575-0775
Employees835

Debt

Debt-to-Equity Ratio2.95
Current Ratio1.78
Quick Ratio1.35

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$260.98 million
Price / Sales1.67
Cash FlowN/A
Price / Cash FlowN/A
Book Value$0.59 per share
Price / Book7.00

Profitability

EPS (Most Recent Fiscal Year)($0.42)
Net Income$-40,450,000.00
Net Margins-13.58%
Return on Equity-101.41%
Return on Assets-17.86%

Miscellaneous

Outstanding Shares105,417,000
Market Cap$435.37 million
Next Earnings Date11/10/2020 (Estimated)
OptionableNot Optionable
$4.13
+0.01 (+0.24 %)
(As of 10/20/2020 10:37 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive ORGO News and Ratings via Email

Sign-up to receive the latest news and ratings for ORGO and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Organogenesis (NASDAQ:ORGO) Frequently Asked Questions

How has Organogenesis' stock price been impacted by COVID-19 (Coronavirus)?

Organogenesis' stock was trading at $2.98 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, ORGO stock has increased by 38.6% and is now trading at $4.13.
View which stocks have been most impacted by COVID-19.

Do Wall Street analysts recommend investors buy shares of Organogenesis?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Organogenesis in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Organogenesis.

When is Organogenesis' next earnings date?

Organogenesis is scheduled to release its next quarterly earnings announcement on Tuesday, November 10th 2020.
View our earnings forecast for Organogenesis.

How were Organogenesis' earnings last quarter?

Organogenesis Holdings Inc. (NASDAQ:ORGO) issued its quarterly earnings results on Monday, August, 10th. The company reported ($0.05) earnings per share for the quarter, beating the Zacks' consensus estimate of ($0.12) by $0.07. The firm earned $68.96 million during the quarter, compared to the consensus estimate of $68.30 million. Organogenesis had a negative return on equity of 101.41% and a negative net margin of 13.58%.
View Organogenesis' earnings history.

What guidance has Organogenesis issued on next quarter's earnings?

Organogenesis updated its FY 2020 After-Hours earnings guidance on Wednesday, October, 14th. The company provided EPS guidance of for the period. The company issued revenue guidance of $311-314 million, compared to the consensus revenue estimate of $275.12 million.

What price target have analysts set for ORGO?

4 equities research analysts have issued 12-month price targets for Organogenesis' stock. Their forecasts range from $7.00 to $10.00. On average, they anticipate Organogenesis' stock price to reach $8.75 in the next twelve months. This suggests a possible upside of 111.9% from the stock's current price.
View analysts' price targets for Organogenesis.

Who are some of Organogenesis' key competitors?

Some companies that are related to Organogenesis include Zentalis Pharmaceuticals (ZNTL), Revance Therapeutics (RVNC), uniQure (QURE), ZEALAND PHARMA/S (ZEAL), CytoDyn (CYDY), Northwest Biotherapeutics (NWBO), Ironwood Pharmaceuticals (IRWD), Y-mAbs Therapeutics (YMAB), Rocket Pharmaceuticals (RCKT), Amneal Pharmaceuticals (AMRX), ALX Oncology (ALXO), Ligand Pharmaceuticals (LGND), Dicerna Pharmaceuticals (DRNA), Myovant Sciences (MYOV) and Trillium Therapeutics (TRIL).
View all competitors.

What other stocks do shareholders of Organogenesis own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Organogenesis investors own include Strongbridge Biopharma (SBBP), vTv Therapeutics (VTVT), Cerecor (CERC), TapImmune (MRKR), Matinas BioPharma (MTNB), Opko Health (OPK), Ovid Therapeutics (OVID), Sorrento Therapeutics (SRNE), DURECT (DRRX) and Evofem Biosciences (EVFM).

Who are Organogenesis' key executives?

Organogenesis' management team includes the following people:
  • Mr. Gary S. Gillheeney Sr., Pres, CEO & Director (Age 65, Pay $1.44M)
  • Ms. Lori H. Freedman, VP & Gen. Counsel (Age 53, Pay $508.71k)
  • Mr. Brian Grow, Chief Commercial Officer (Age 44, Pay $605.8k)
  • Mr. Henry Hagopian III, Interim CFO, VP of Fin. & Treasurer (Age 52)
  • Mr. Patrick Bilbo, Chief Operating Officer (Age 58)
  • Mr. Thomas L. Pearl, VP of HR
  • Dr. Zorina Pitkin, Sr. VP of Quality Systems

What is Organogenesis' stock symbol?

Organogenesis trades on the NASDAQ under the ticker symbol "ORGO."

How do I buy shares of Organogenesis?

Shares of ORGO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Organogenesis' stock price today?

One share of ORGO stock can currently be purchased for approximately $4.13.

How big of a company is Organogenesis?

Organogenesis has a market capitalization of $435.37 million and generates $260.98 million in revenue each year. The company earns $-40,450,000.00 in net income (profit) each year or ($0.42) on an earnings per share basis. Organogenesis employs 835 workers across the globe.

What is Organogenesis' official website?

The official website for Organogenesis is organogenesis.com.

How can I contact Organogenesis?

Organogenesis' mailing address is 85 Dan Road, Canton MA, 02021. The company can be reached via phone at 781-575-0775 or via email at [email protected]

This page was last updated on 10/20/2020 by MarketBeat.com Staff
Receive Analysts' Upgrades and Downgrades Daily

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.